Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT04553770 ·Status: RECRUITING ·Phase: PHASE2

An Observational Study of Herceptin SC Safety in Breast Cancer

NCT02305628 ·Status: COMPLETED

Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study

NCT06843681 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2

A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease

NCT00679341 ·Status: COMPLETED ·Phase: PHASE2

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

NCT07047755 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan

NCT06504719 ·Status: COMPLETED

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

NCT06027983 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

NCT05950945 ·Status: RECRUITING ·Phase: PHASE3

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

NCT06585969 ·Status: WITHDRAWN ·Phase: PHASE3

A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

NCT02510781 ·Status: UNKNOWN ·Phase: PHASE2

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT02131064 ·Status: COMPLETED ·Phase: PHASE3

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

NCT02326974 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

NCT02586025 ·Status: COMPLETED ·Phase: PHASE3

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors

NCT00433407 ·Status: COMPLETED ·Phase: NA

An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)

NCT02658461 ·Status: COMPLETED

Identification of Early Markers of Response and Resistance to Trastuzumab

NCT01834950 ·Status: COMPLETED ·Phase: NA

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

NCT00381901 ·Status: COMPLETED ·Phase: PHASE3

Phase II Study of Herzuma® Plus Gedatolisib in Patients With HER-2 Positive Metastatic Breast Cancer

NCT03698383 ·Status: UNKNOWN ·Phase: PHASE2

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

NCT06750484 ·Status: RECRUITING ·Phase: PHASE2

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

NCT02605915 ·Status: COMPLETED ·Phase: PHASE1

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

NCT07179939 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

NCT07073755 ·Status: RECRUITING

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

NCT06330012 ·Status: RECRUITING ·Phase: NA